Patent · US Active

Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

US11285159B2 · kind B2 · utility

0Cited by

53References

42Claims

0Family size

Assignees

Abb Vie Inc. · US
Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

John Hayslip · Lexington, US
Leanne M. Holes · Bothell, US
Sven Mensing · Mannheim, DE
Silpa Nuthalapati · Vernon Hills, US

Key dates

Filing date	Nov 4, 2020
Grant date	Mar 29, 2022
Priority date	—
Expiry date	Nov 4, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.